Headline: US Imposes 100% Tariff Threat on Pharmaceuticals to Boost Domestic Production

Why this matters: The policy could reshape global pharmaceutical trade, affecting drug prices, supply chains, and industry investment decisions.

Date: 2 April 2026

Tags: Business, Trade, Health, US

Summary:

• Donald Trump announced potential 100% tariffs on patented medicines entering the US.

• Policy aims to boost domestic pharmaceutical manufacturing for national security.

• Generic medicines excluded from tariffs, limiting immediate widespread impact.

• Companies can avoid tariffs by investing in US manufacturing facilities.

• Firms agreeing to pricing deals could see tariffs reduced to zero.

• Large pharmaceutical companies have already secured agreements to avoid levies.

• Smaller firms risk higher costs if unable to negotiate exemptions.

• US gave companies 120–180 days to reach agreements.

• UK and US previously agreed zero tariffs on UK pharmaceutical exports.

• Tariff threat has reportedly driven $400bn in pledged US investments.

What’s next: Companies are expected to negotiate deals with the US government to avoid tariffs before deadlines expire.